Establishment Labs (NASDAQ:ESTA) Price Target Cut to $74.00 by Analysts at Citigroup

Establishment Labs (NASDAQ:ESTA) had its price objective trimmed by Citigroup from $81.00 to $74.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a neutral rating on the stock.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. upped their price target on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded Establishment Labs from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. BTIG Research upped their target price on Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Canaccord Genuity Group increased their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Stephens raised their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Establishment Labs currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.86.

Establishment Labs Trading Down 0.2%

Establishment Labs stock opened at $66.24 on Wednesday. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $83.31. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -38.07 and a beta of 0.91. The company has a 50 day moving average price of $70.55 and a 200 day moving average price of $60.23.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.13. The company had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The company’s revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the business earned ($1.19) EPS. Research analysts forecast that Establishment Labs will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Establishment Labs by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after purchasing an additional 299 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its stake in shares of Establishment Labs by 5.8% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company’s stock valued at $261,000 after buying an additional 350 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Establishment Labs by 7.3% in the fourth quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $641,000 after buying an additional 600 shares during the last quarter. Swiss National Bank increased its holdings in Establishment Labs by 1.8% in the fourth quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after buying an additional 600 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Establishment Labs during the fourth quarter valued at approximately $47,000. 72.91% of the stock is owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.